BVS — Bioventus Inc.

Summary of Bioventus Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $158 million, a 3% increase year-over-year; organic growth was 10%.
• Adjusted EBITDA: $37 million, up $8 million (30% increase) from the prior year, with an adjusted EBITDA margin of 23%, expanding by 490 basis points.
• Adjusted Earnings per Share: $0.24 for the quarter.
• Cash Flow from Operations: $38 million, nearly double compared to Q4 2024, contributing to a full-year cash flow of nearly $75 million, achieving a 92% increase year-over-year.
• Debt: $94 million outstanding, with a net leverage ratio below 2.5 times, down from previous levels.

2. Strategic Updates and Business Highlights

• Bioventus is transitioning into a new phase focused on accelerating revenue growth while enhancing profitability and cash flow.
• The company reported strong performance in its pain treatments and restorative therapies segments, with notable growth from its Duralane product.
• New growth drivers include Peripheral Nerve Stimulation (PNS) and Platelet-Rich Plasma (PRP), both receiving positive feedback from pilot launches.
• The company plans to invest approximately $13 million in growth drivers, particularly in PNS and Ultrasonics, to drive future growth.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected net sales between $600 million and $610 million, with growth anticipated to accelerate in the second half of the year.
• Earnings Guidance: Adjusted earnings per share projected at $0.73 to $0.77, indicating growth that outpaces revenue growth.
• Cash Flow Guidance: Expected cash from operations to range between $82 million and $87 million, a 10% to 17% increase.
• The company aims to maintain an EBITDA margin of approximately 20% for 2026.

4. Bad News, Challenges, or Points of Concern

• International Segment Performance: Revenue was unchanged year-over-year, indicating challenges in distributor order timing.
• Restorative Therapies Decline: Revenue declined 26% due to the divestiture of the Advanced Rehabilitation business, although organic growth was 10% when excluding this impact.
• Market Dynamics: The company anticipates a deceleration in organic growth in the first half of 2026, influenced by fewer selling days and inventory normalization.

5. Notable Q&A Insights

• Management acknowledged that the strong Q4 performance was aided by favorable order timing and selling days, which may not be sustainable into Q1 2026.
• The PNS pilot launch provided valuable insights, confirming the technology's differentiation and ease of use, which will guide aggressive scaling in 2026.
• The company reaffirmed expectations for a minimum 200 basis points of growth contribution from PNS and PRP combined in 2026.
• Ultrasonics is a key focus area, with plans to expand sales and marketing efforts to enhance awareness and adoption.

Overall, Bioventus Inc. demonstrated strong financial performance in Q4 2025, setting a solid foundation for growth in 2026 while navigating some challenges in specific segments and market dynamics.